Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of PCV13 and PPV23 in HIV-infected Adults
NCT03041051Phase 4Unknown
- Sponsor
- Aghia Sophia Children's Hospital of Athens
- Start
- Dec 2015
- Primary completion
- Mar 2017
- Modality
- Split/Subunit Vaccines
01
Overview
Phase 4, open-label trial of Prevnar 13 and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (2 arms), sponsored by Aghia Sophia Children's Hospital of Athens. Primary endpoints: Immunoglobulin G (IgG) B memory cell response and Immunoglobulin M (IgM) B memory cell response. Status: unknown.
02
Drugs
Prevnar 1323-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT03041051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041051.